Aimed Alliance Signs on to Coalition for Accessible Treatments Letter
Aimed Alliance has signed on to the Coalition for Accessible Treatments’ letter commenting on the…
Browsing: Federal
CMS’s “Creative Accounting” for Insurance Co-Ops Comes under Question
The Centers for Medicare and Medicaid Services (CMS) was scrutinized by two senate committee leaders…
White House Confirms Steep 2016 Obamacare Premium Hikes
Report Highlights Need for Policy Solutions to Improve Industry Shortcomings Washington, D.C. – The Obama…
Aimed Alliance Signs on to “I Am Essential” Coalition Letter
Aimed Alliance has signed on to the “I Am Essential” coalition’s letter, urging the United…
Aimed Alliance Submits Comment to FDA on Approval of Generic Chronic Dry Eye Med
Earlier today, Aimed Alliance’s Director of Public Policy, Stacey L. Worthy, submitted a comment to…
Aimed Alliance Presents Testimony Urging FDA Panel’s Approval of Novel Treatment
Today, Aimed Alliance presented testimony before a joint meeting of the U.S. Food and Drug…
FDA Releases Much-Anticipated Guidelines on Biosimilar Naming
This week, the U.S. Food and Drug Administration (FDA) released its much-anticipated guidelines on the…
Aimed Alliance Signs on to 21st Century Cures Letter
Today, the National Health Council sent a letter signed by Aimed Alliance and 250 other…
FDA Releases Three Final Guidances on Biosimilars
The U.S. Food and Drug Administration (FDA) has issued three final guidances on biosimilars, which…
Aimed Alliance Participates in CBI’s Q&A
In preparation for CBI’s Abuse Deterrent Formulations Summit, at which Aimed Alliance’s Director of Public…